Incyte

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat
Endpoints
Mon, 06/5/17 - 10:08 am
Incyte
ASCO 2017
epacadostat
non-small cell lung cancer
Keytruda
Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Endpoints
Tue, 05/30/17 - 11:48 am
ASCO
IDO inhibitors
CAR-T
PDL-1 inhibitors
Merck
Incyte
NewLink Genetics
Novartis
Juno Therapeutics
Bristol-Myers Squibb
7 Areas to watch from the ASCO abstracts
BioPharma Dive
Fri, 05/19/17 - 11:35 am
ASCO 2017
oncology
Incyte
Merck
Eli Lilly
CAR-T
NewLink Genetics
Amgen
Roche
Kite Pharma
Juno Therapeutics
Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo
Endpoints
Thu, 05/18/17 - 12:08 am
Incyte
epacadostat
ASCO 2017
Merck
Keytruda
non-small cell lung cancer
Incyte doubles down on CEO Hervé Hoppenot’s pay package — big but not stupid
Endpoints
Tue, 04/18/17 - 09:42 am
Incyte
Pharma CEOs
Hervé Hoppenot
executive pay
The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling
Yahoo/Business Insider
Mon, 04/17/17 - 11:32 am
FDA
rheumatoid arthritis
Eli Lilly
Incyte
baricitinib
Biotech Movers: OncoMed, Incyte, Omeros
TheStreet.com
Mon, 04/17/17 - 11:22 am
biotech
OncoMed
tarextumab
small cell lung cancer
Incyte
Eli Lilly
baricitinib
Omeros
Eli Lilly and Incyte say FDA failed to approve their rheumatoid arthritis drug
Marketwatch
Fri, 04/14/17 - 10:48 am
Eli Lilly
Incyte
FDA
rheumatoid arthritis
baricitinib
Traders say mergers and acquisitions could bring boost to biotech stocks
CNBC
Fri, 04/14/17 - 10:00 am
M&A
biotech
Tesaro
Incyte
We don’t know when (exactly) Lilly will announce the FDA’s baricitinib decision, but watch out for the looming pricing squabble
Endpoints
Thu, 04/13/17 - 11:48 am
Eli Lilly
FDA
baricitinib
drug pricing
Incyte
3 Big Drugmakers Most Likely to Buy Incyte
Motley Fool
Wed, 04/12/17 - 11:57 am
Incyte
M&A
Gilead Sciences
Amgen
Bristol-Myers Squibb
Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
Barron's
Tue, 04/11/17 - 10:07 am
Incyte
epacadostat
olumiant
Jakafi
immuno-oncology
Would Gilead Sciences Make This Staggeringly Audacious Move?
Motley Fool
Sun, 04/9/17 - 12:27 pm
Gilead Sciences
M&A
Celgene
Incyte
Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials
Fierce Pharma
Tue, 04/4/17 - 11:10 pm
Merck
Bristol-Myers Squibb
Incyte
Keytruda
Opdivo
non-small cell lung cancer
4 Drug Stocks With Big News Coming in April
Motley Fool
Tue, 04/4/17 - 12:11 am
Neurocrine
Incyte
Eli Lilly
Biomarin
Ingrezza
baricitinib
Brineura
Merck, Incyte Expand Cancer Collaboration
Barron's
Fri, 03/31/17 - 10:00 pm
Merck
Incyte
epacadostat
Keytruda
melanoma
Gilead Sciences: Is an Incyte Deal ‘Reasonable’?
Barron's
Mon, 03/13/17 - 11:26 am
Gilead Sciences
Incyte
M&A
Tapping into the rare disease market
BioPharma Dive
Fri, 03/10/17 - 09:00 pm
Rare Diseases
Incyte
Horizon Pharma
Lundbeck
Incyte tops Street 4Q forecasts
Yahoo/AP
Tue, 02/14/17 - 12:09 pm
Incyte
earnings
Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company
Motley Fool
Wed, 01/25/17 - 09:53 am
Gilead Sciences
Incyte
M&A
Galapagos

Pages